Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Cross-reactivity00:42

Cross-reactivity

31.0K
Overview
31.0K
Hybridoma Technology01:31

Hybridoma Technology

14.4K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
14.4K
Antibody Actions01:26

Antibody Actions

1.1K
Antibodies, or immunoglobulins, are critical players in the immune system's arsenal against invading pathogens. Produced by B cells and plasma cells, their primary role is to detect and bind to specific antigens, molecules found on the surface of pathogens like bacteria or viruses. Beyond antigen recognition, antibodies perform several vital functions that contribute to immune defense.
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...
1.1K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Identification and Optimization of a Truncated Hs-1-Derived Antimicrobial Peptide for Enhanced Broad-Spectrum Antiviral Activity.

ChemMedChem·2026
Same author

Neurofeedback of somatosensory alpha oscillations modulates sensory and affective pain through dissociable neurocognitive pathways.

Pain·2026
Same author

Human parainfluenza virus 3 fusion protein cleavage: a key determinant of infection and spread.

Journal of virology·2026
Same author

Structural overview of lyssavirus glycoproteins, antibodies, and receptors.

Journal of virology·2026
Same author

The Gut Microbiota-Polyphenol-NLRP3 Inflammasome Axis: A Key Regulatory Network Linking Diet to Chronic Inflammation.

Nutrients·2026
Same author

Developmental candidate GHP-88310/EIDD-3608 with high tolerability and oral efficacy in measles and respiratory paramyxovirus models.

Science advances·2026

相关实验视频

Updated: Jun 22, 2025

Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics DCAF
09:39

Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics DCAF

Published on: September 17, 2019

6.9K

中和抗体防止麻疹病毒融合蛋白的融合后转变

Dawid S Zyla1, Roberta Della Marca2,3,4, Gele Niemeyer1,5

  • 1Center for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA 92037, USA.

Science (New York, N.Y.)
|June 27, 2024
PubMed
概括

由于疫苗接种率下降,麻疹病毒 (MeV) 构成越来越大的威胁. 研究人员从结构上描述了中和抗体,揭示了它们如何阻断潜在的新型MeV疗法.

更多相关视频

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

9.5K
Generation of Escape Variants of Neutralizing Influenza Virus Monoclonal Antibodies
07:55

Generation of Escape Variants of Neutralizing Influenza Virus Monoclonal Antibodies

Published on: August 29, 2017

11.8K

相关实验视频

Last Updated: Jun 22, 2025

Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics DCAF
09:39

Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics DCAF

Published on: September 17, 2019

6.9K
Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

9.5K
Generation of Escape Variants of Neutralizing Influenza Virus Monoclonal Antibodies
07:55

Generation of Escape Variants of Neutralizing Influenza Virus Monoclonal Antibodies

Published on: August 29, 2017

11.8K

科学领域:

  • 病毒学
  • 结构生物学
  • 免疫学

背景情况:

  • 麻疹病毒 (MeV) 是一个严重的公共卫生问题,由于疫苗接种率的下降和免疫受损人口的增加而加剧.
  • 目前没有有效的治疗方法来治疗MeV感染.
  • 针对病毒融合 (F) 蛋白的中和抗体是一个有前途的治疗途径,但缺乏结构特征.

研究的目的:

  • 在其注射前和注射后状态下对麻疹病毒融合 (F) 蛋白进行结构性表征.
  • 通过针对MeV的保护性单克隆抗体 (mAb) 77阐明中和机制.
  • 为开发新型MeV疗法提供结构性见解.

主要方法:

  • 使用冷电子显微镜 (cryo-EM) 来确定MeV F蛋白的高分辨率结构.
  • 解决了单独预注射F的结构,F与融合抑制复合,F与mAb77复合.
  • 为了验证mAb 77结合的功能作用,进行了体外测试.

主要成果:

  • 获得了融合前和融合后的MeV F蛋白的高分辨率冷EM结构 (2.1-2.7 Å分辨率).
  • 显示单克隆抗体77与前输F蛋白结合.
  • 观察到mAb77可以在中间状态下捕获F蛋白,防止其过渡到融合后的形状.

结论:

  • 结构数据揭示了mAb 77通过稳定中间融合形态来中和MeV的机制.
  • 这些发现为设计针对麻疹的融合抑制疗法提供了结构性基础.
  • 这项研究强调了针对病毒融合蛋白来开发抗病毒药物的可能性.